Eli Lilly And Company (LLY): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Eli Lilly and Company ( LLY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 3.6%. By the end of trading, Eli Lilly and Company fell $0.83 (-1.4%) to $60.03 on average volume. Throughout the day, 6,004,352 shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5,393,000 shares. The stock ranged in price between $59.97-$61.15 after having opened the day at $60.97 as compared to the previous trading day's close of $60.86. Other companies within the Drugs industry that declined today were: DARA Biosciences ( DARA), down 14.1%, Aoxing Pharmaceutical Company ( AXN), down 9.0%, 22nd Century Group ( XXII), down 7.3% and Codexis ( CDXS), down 7.2%.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and Company has a market cap of $67.7 billion and is part of the health care sector. Shares are up 19.3% year to date as of the close of trading on Monday. Currently there are 6 analysts that rate Eli Lilly and Company a buy, 2 analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, GW Pharmaceuticals ( GWPH), up 32.2%, Revance Therapeutics ( RVNC), up 25.8%, Evoke Pharma ( EVOK), up 18.2% and Idera Pharmaceuticals ( IDRA), up 16.9% , were all gainers within the drugs industry with Gilead ( GILD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

Here's How Eli Lilly Stock Can Regain Its Footing

Here's How Eli Lilly Stock Can Regain Its Footing

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices